BOSTON ( TheStreet) -- For FDA drug approval decision junkies, October is your World Cup.

By my count, U.S. regulators will issue approval decisions on 13 different drugs during October, making it the busiest month on the FDA calendar by a large margin. The summer -- when news flow in the biotech sector slows down and investor interest wanes -- is a good time to start thinking about the uptick of biotech catalysts in the fall.

For this June update to my regular FDA regulatory calendar, I've highlighted the 13 drugs (impacting 19 different companies) awaiting approval decisions in October. Stocks are listed in chronological order, starting with the earliest FDA approval decision date.

Read on.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women